Literature DB >> 12785294

Cefpodoxime: pharmacokinetics and therapeutic uses.

Krishan Chugh1, Shruti Agrawal.   

Abstract

Cefpodoxime is a semi-synthetic, third generation cephalosporin. The drug is available for use as a prodrug-Cefpodoxime proxetil, which is absorbed readily from the gut. It reaches adequate levels exceeding the MIC in most of the body fluids. It is excreted by kidneys, unchanged. Dose needs adjustment in compromised renal function. The drug is active against common gram-positive cocci like staphylococci including penicillinase producing strains, streptococci and gram negative bacteria like Hemophilus, E. coli, Klebsiella, Moraxella, Meningococci, Gonococci etc. The drug is useful in common upper and lower respiratory tract infections, sinusitis, and otitis media. The drug is also used in skin and soft tissue infections, urinary tract infection and respiratory tract infection. Cefpodoxime is being used as a step down from parenteral cephalosporin. The recommended dose is 8-10 mg/kg/d in a single or two doses. Different schedules have been given for different infections. The drug is safe, effective as a short course (5 vs. 10 days). With a low incidence of side effects, and twice a day dosing, it proves to be a useful drug.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12785294     DOI: 10.1007/bf02725589

Source DB:  PubMed          Journal:  Indian J Pediatr        ISSN: 0019-5456            Impact factor:   1.967


  10 in total

Review 1.  Summary of clinical experience with cefpodoxime proxetil in adults in Japan.

Authors:  J Kumazawa
Journal:  Drugs       Date:  1991       Impact factor: 9.546

Review 2.  A review of the pharmacokinetics of cefpodoxime proxetil.

Authors:  M T Borin
Journal:  Drugs       Date:  1991       Impact factor: 9.546

Review 3.  Sequential therapy with intravenous and oral cephalosporins.

Authors:  R Janknegt; J W van der Meer
Journal:  J Antimicrob Chemother       Date:  1994-01       Impact factor: 5.790

Review 4.  Cefpodoxime proxetil: a review of its use in the management of bacterial infections in paediatric patients.

Authors:  B Fulton; C M Perry
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

5.  Comparison of oral cefpodoxime proxetil and cefaclor in the treatment of skin and soft tissue infections.

Authors:  D L Stevens; F Pien; M Drehobl
Journal:  Diagn Microbiol Infect Dis       Date:  1993-02       Impact factor: 2.803

6.  Cefpodoxime pharmacokinetics in children: effect of food.

Authors:  G L Kearns; S M Abdel-Rahman; R F Jacobs; T G Wells; M T Borin
Journal:  Pediatr Infect Dis J       Date:  1998-09       Impact factor: 2.129

Review 7.  Cefpodoxime proxetil. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential.

Authors:  J E Frampton; R N Brogden; H D Langtry; M M Buckley
Journal:  Drugs       Date:  1992-11       Impact factor: 9.546

8.  The sensitivity of 173 Sydney isolates of Neisseria gonorrhoeae to cefpodoxime and other antibiotics used to treat gonorrhea.

Authors:  J W Tapsall; E A Phillips
Journal:  Pathology       Date:  1995-01       Impact factor: 5.306

9.  Pharmacoeconomic benefit of antibiotic step-down therapy: converting patients from intravenous ceftriaxone to oral cefpodoxime proxetil.

Authors:  J R Hendrickson; D S North
Journal:  Ann Pharmacother       Date:  1995-06       Impact factor: 3.154

10.  Orally administered cefpodoxime proxetil for treatment of uncomplicated gonococcal urethritis in males: a dose-response study.

Authors:  E Novak; L M Paxton; H J Tubbs; L F Turner; C W Keck; J Yatsu
Journal:  Antimicrob Agents Chemother       Date:  1992-08       Impact factor: 5.191

  10 in total
  1 in total

Review 1.  FDA-Approved Oximes and Their Significance in Medicinal Chemistry.

Authors:  Jyothi Dhuguru; Eugene Zviagin; Rachid Skouta
Journal:  Pharmaceuticals (Basel)       Date:  2022-01-04
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.